The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma

Gene Therapy

Volumn 12, Issue 20, 2005, Pages 1526-1533

  Xu, D P ^a   Sauter, B V ^a   Huang, T G ^a   Meseck, M ^a   Woo, S L C ^a   Chen, S H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

4 1BB ligand; IL 12; Immune modulation; NK and T cells

Indexed keywords

CD137 LIGAND; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; GENE FUSION; GENE TRANSFER; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; LIVER CARCINOMA; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PURIFICATION; SPLEEN LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM;

4-1BB LIGAND; ADENOVIRIDAE; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CELLS, CULTURED; COLONIC NEOPLASMS; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTORS;

ADENOVIRIDAE;

EID: 27144497304     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302556     Document Type: Article

References (20)

1. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998; 10: 481-489.
2. Kwon B et al. 4-1BB: Still in the midst of darkness. Mol Cells 2000; 10: 119-126.
3. Pollok KE et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150: 771-781.
4. Melero I et al. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190: 167-172.
5. Futagawa T et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14: 275-286.
6. Wilcox RA et al. Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol 2002; 168: 4262-4267.
7. Pan PY et al. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 2004; 172: 4779-4789.
8. Cannons JL et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001; 167: 1313-1324.
9. Kim YJ, Broxmeyer HE. Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8 (+) T cells. J Hematother Stem Cell Res 2001; 10: 441-449.
10. Melero I et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-685.
11. Kim JA et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001; 61: 2031-2037.
12. Martinet O et al. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Therapy 2002; 9: 786-792.
13. Martinet O et al. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92: 931-936.
14. Chen SH et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2000; 2: 39-46.
15. Wilcox RA et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109: 651-659.
16. Pullen SS et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 1999; 38: 10168-10177.
17. Ye H, Wu H. Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry. Proc Natl Acad Sci USA 2000; 97: 8961-8966.
18. Morris AE et al. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999; 274: 418-423.
19. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
20. Holmes K, Fowlkes BJ. Preparation of cells and reagents for flow cytometry. In: Coligam JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W (eds). Current Protocols in Immunology. John Wiley & Sons, Inc.: USA, 1991, pp 5.3.1-5.3.23.